PMID- 36444274
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221202
IS  - 2666-6065 (Electronic)
IS  - 2666-6065 (Linking)
VI  - 30
DP  - 2023 Jan
TI  - Establishing baseline framework for hepatitis B virus micro-elimination in Ho Chi 
      Minh City, Vietnam - A community-based seroprevalence study.
PG  - 100620
LID - 10.1016/j.lanwpc.2022.100620 [doi]
LID - 100620
AB  - BACKGROUND: We conducted a community-based seroprevalence study using three HBV 
      seromarkers (HBsAg, anti-HBs, anti-HBc) in Ho Chi Minh City (HCMC), Vietnam, to 
      (1) determine the prevalence of HBV serologic profiles; (2) document factors 
      associated with HBV infection or susceptibility; and (3) propose strategies 
      toward HBV elimination by 2030. METHODS: During 2019-2020, we deployed a 
      multistage cluster design with probability proportionate to size, to recruit 
      20,000 adults for an HBV screening and linkage to care program citywide. 
      Screening results with interpretation, recommendations, and health education 
      materials were returned to participants. Post-study surveys were conducted within 
      three months to identify gaps in linkage to care. FINDINGS: Of the 17,600 adults 
      invited, 15,275 (86.7%) participated in the study, 14,674 (96.1%) completing all 
      data for final analyses. The prevalence of HBsAg (+) and HBV-naive were 7.5% and 
      37.7%, respectively. HBV vaccination rates were 18.7% and about 50% of HCMC 
      population had been exposed to HBV. Of the persons with HBsAg (+), 27.1% linked 
      to care (76% used health insurance). There were wide variations in HBsAg (+) and 
      HBV vaccination rates between districts, risk factors, and socio-economic 
      statuses. INTERPRETATION: The significant disease burden of and gaps in the 
      continuum of care highlight the need and urgency to address the HBV public health 
      problem in Vietnam. Using three screening seromarkers that tailor interventions 
      to the needs of HBV micro-populations could be an effective strategy to pursue 
      HBV elimination goals. FUNDING: Gilead Sciences Inc; Roche Diagnostic 
      International Ltd; Roche Diagnostics-Vietnam; Abbott Diagnostics-Vietnam; 
      Hepatitis B Foundation; Medic MedicalCenter, Vietnam; Center of Excellence for 
      Liver Disease in Vietnam, Johns Hopkins University School of Medicine.
CI  - (c) 2022 The Author(s).
FAU - Pham, Trang N D
AU  - Pham TND
AD  - Department of Epidemiology and Biostatistics, School of Public Health, University 
      of Illinois at Chicago, Chicago, IL, USA.
AD  - Department of Biomedical and Health Information Sciences, College of Applied 
      Health Sciences, University of Illinois at Chicago, Chicago, IL, USA.
AD  - Center of Innovation for Complex Chronic Healthcare (CINNCH), Hines VA Hospital, 
      Hines, IL, USA.
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
AD  - Hung Vuong Hospital, Ho Chi Minh City, Vietnam.
FAU - Le, Duc H
AU  - Le DH
AD  - Department of Epidemiology, Faculty of Public Health, Pham Ngoc Thach University 
      of Medicine, Ho Chi Minh City, Vietnam.
FAU - Dao, Diem V B
AU  - Dao DVB
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
FAU - Phan, Loc T B
AU  - Phan LTB
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
FAU - Pham, Thuy T T
AU  - Pham TTT
AD  - Medic Medical Center, Ho Chi Minh City, Vietnam.
FAU - Nguyen, Toan B
AU  - Nguyen TB
AD  - Medic Medical Center, Ho Chi Minh City, Vietnam.
FAU - Mize, Gary W
AU  - Mize GW
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
FAU - Gish, Robert G
AU  - Gish RG
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
AD  - Hepatitis B Foundation, Doylestown, PA, USA.
FAU - Lee, William M
AU  - Lee WM
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
AD  - UT Southwestern Medical Center, Dallas, TX, USA.
FAU - Trang, Amy
AU  - Trang A
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
FAU - Le, Anh N
AU  - Le AN
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
FAU - Chen, Moon Jr
AU  - Chen M Jr
AD  - University of California at Davis, Davis, CA, USA.
FAU - Phan, Hai T
AU  - Phan HT
AD  - Medic Medical Center, Ho Chi Minh City, Vietnam.
FAU - Nguyen, Binh T
AU  - Nguyen BT
AD  - Ho Chi Minh City Department of Health, Ho Chi Minh City, Vietnam.
FAU - Tang, Hong K
AU  - Tang HK
AD  - Department of Epidemiology, Faculty of Public Health, Pham Ngoc Thach University 
      of Medicine, Ho Chi Minh City, Vietnam.
FAU - Dao, Doan Y
AU  - Dao DY
AD  - Vietnam Viral Hepatitis Alliance, Reston, VA, USA.
AD  - Center of Excellence for Liver Disease in Vietnam, Johns Hopkins University 
      School of Medicine, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
DEP - 20221029
PL  - England
TA  - Lancet Reg Health West Pac
JT  - The Lancet regional health. Western Pacific
JID - 101774968
PMC - PMC9700320
OTO - NOTNLM
OT  - 2030
OT  - HBV linkage to care
OT  - HBV screening
OT  - Hepatitis B virus
OT  - Ho Chi Minh City (HCMC)
OT  - Micro-elimination
OT  - National elimination
OT  - Vietnam
COIS- MC.Jr received consulting fees from the Vietnam Viral Hepatitis Alliance. RGG has 
      received grants or research support in last two years from Gilead. RGG has also 
      performed as a consultant or advisor in the past two years to Abbott, AbbVie, 
      Altimunne, Antios, Arrow head, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, 
      Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, 
      Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or 
      clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, 
      Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. 
      RGG is a member of Topography Health clinical trials alliance. RGG is chair of 
      the clinical advisory board for Prodigy. RGG is an advisory consultant for 
      Fibronostics, Fujifilm/Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data 
      safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and 
      Durect. RGG currently has consulting confidentiality agreements with Abbvie, 
      Abbott, Access Biologicals, Active Genome Expressed Diagnostics, ADMA Biologics, 
      AEC Partners, Aligos Therapeutics, Arena Pharma ceuticals Inc, Ark 
      Biopharmaceutical Co Ltd, Arrowhead, Arterys Inc, Alexion, Altimmune, Antios 
      Therapeutics, AprosTx, Audentes Therapeutics, Bayer, Bausch/Salix, Cirina, 
      Consumer Health Products Assoc, CymaBay Therapeutics Inc, DiaSorin Inc, Dova 
      Pharmaceuticals, DRG Abacus, DURECT Corporation, Dynavax, Echosens, Eiger, Eisai, 
      Enyo, Exelixis, Fibronostics Inc, Forty-Seven Inc, Fujifilm Wako Diagnostics, 
      Gilead, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, 
      Janssen/J&J, KannaLife, Kezar Life Sciences Inc, LabCorp, Laboratory for Advanced 
      Medicine, Labyrinth Holdings, Life Line Screening, Lilly, MedImmune, Merck, New 
      Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, 
      Perspectum, Pfizer, Pharmaceutical Research Associates, ProdigY Biotech, 
      Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Sagimet Inc, 
      Salix, Saol Bermuda Ltd, Shenzhen HEC Industrial Develop ment, Shionogi Inc, 
      Spring Bank, Tonghua Anrate Biopharmaceutical, Topography Health, Trimaran, 
      Venatorx, and Viravaxx AG. RGG reports activities for Speakers Bureau, focusing 
      on HBV, HCV, HDV and liver cancer; specifically, epidemiology, diagnosis, and 
      treatment. In addition, program presentations on vaccination for HBV and 
      management of complications of cirrhosis. RGG has speaker's contracts to do 
      promotional talks for AbbVie, BMS, Eisai, Genentech, Gilead Sciences Inc., and 
      Intercept. RGG is a minor stock shareholder (liver space noted only) for 
      RiboSciences and CoCrystal. RGG holds stock options in Eiger, Gen lantis, 
      HepQuant, AngioCrine, and HepaTx, outside the submitted work. The rest of the 
      authors declare no competing interests.
EDAT- 2022/11/30 06:00
MHDA- 2022/11/30 06:01
PMCR- 2022/10/29
CRDT- 2022/11/29 01:47
PHST- 2022/06/24 00:00 [received]
PHST- 2022/08/21 00:00 [revised]
PHST- 2022/10/05 00:00 [accepted]
PHST- 2022/11/29 01:47 [entrez]
PHST- 2022/11/30 06:00 [pubmed]
PHST- 2022/11/30 06:01 [medline]
PHST- 2022/10/29 00:00 [pmc-release]
AID - S2666-6065(22)00235-8 [pii]
AID - 100620 [pii]
AID - 10.1016/j.lanwpc.2022.100620 [doi]
PST - epublish
SO  - Lancet Reg Health West Pac. 2022 Oct 29;30:100620. doi: 
      10.1016/j.lanwpc.2022.100620. eCollection 2023 Jan.